NASDAQ (usa) arrow 6715.56 -12.11 -0.18%
FTSE 100 (london) arrow 7487.96 -5.12 -0.07%
DAX (german) arrow 13465.51 235.94 1.78%
NIKKEI 225 (japan) arrow 22420.08 408.47 1.86%
Hang - Seng (hong kong) arrow 28594.06 348.52 1.23%
NIFTY - 50 (india)
Straits Times (singapore) arrow 3391.61 17.53 0.52%
KOSPI (korea) arrow 2556.47 33.04 1.31%
All Ordinaries (australia) arrow 6005.30 28.90 0.48%
BOVESPA (brazil) arrow 74092.76 -215.73 -0.29%

Ionis Pharmaceuticals Inc (F: ISI)

 
ISI Technical Analysis
5
As on 5th Feb 2025 ISI STOCK Price closed @ 30.06 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 41.82 & Strong Sell for SHORT-TERM with Stoploss of 41.18 we also expect STOCK to react on Following IMPORTANT LEVELS.
 
 

ISISTOCK Price

Open 30.06 Change Price %
High 30.06 1 Day -0.89 -2.88
Low 30.06 1 Week -2.44 -7.51
Close 30.06 1 Month -5.93 -16.48
Volume 400 1 Year -6.78 -18.40
52 Week High 48.82 | 52 Week Low 30.08
 
F Germany Most Active Stocks
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
IMU 0.10 -99.65%
ENB 47.60 -0.92%
TEF 3.84 -0.52%
TEF 3.84 -0.52%
WHL 5150.00 -0.44%
WDI 0.05 -37.50%
 
F Germany Top Gainers Stocks
JYR 1000000.00 10000000000.00%
JYR 1000000.00 10000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
LAW 1000000.00 5000000000.00%
0AI 11.30 14025.00%
0AI 11.30 14025.00%
SUE1 12.60 12500.00%
HGF2 7.40 1380.00%
 
F Germany Top Losers Stocks
07K 0.00 -100.00%
07K 0.00 -100.00%
07K 0.00 -100.00%
M2G 0.00 -100.00%
M2G 0.00 -100.00%
M2G 0.00 -100.00%
NUB 0.00 -100.00%
NUB 0.00 -100.00%
TINC 0.01 -99.92%
TINC 0.01 -99.92%
 
 
ISI
Daily Charts
ISI
Intraday Charts
Whats New @
Bazaartrend
ISI
Free Analysis
 
ISI Important Levels Intraday
RESISTANCE30.06
RESISTANCE30.06
RESISTANCE30.06
RESISTANCE30.06
RESISTANCE30.06
RESISTANCE30.06
RESISTANCE30.06
RESISTANCE30.06
 
ISI Forecast February 2025
4th UP Forecast45.8
3rd UP Forecast40.75
2nd UP Forecast37.63
1st UP Forecast34.51
1st DOWN Forecast25.61
2nd DOWN Forecast22.49
3rd DOWN Forecast19.37
4th DOWN Forecast14.32
 
ISI Weekly Forecast
4th UP Forecast31.97
3rd UP Forecast31.36
2nd UP Forecast30.98
1st UP Forecast30.60
1st DOWN Forecast29.52
2nd DOWN Forecast29.14
3rd DOWN Forecast28.76
4th DOWN Forecast28.15
 
ISI Forecast2025
4th UP Forecast66.56
3rd UP Forecast54.85
2nd UP Forecast47.62
1st UP Forecast40.38
1st DOWN Forecast19.74
2nd DOWN Forecast12.5
3rd DOWN Forecast5.27
4th DOWN Forecast-6.44
 
 
ISI Other Details
Segment EQ
Market Capital 3619034624.00
Sector Healthcare
Industry Biotechnology
Offical website >
 
ISI Address
ISI
 
ISI Latest News
 
Your Comments and Response on Ionis Pharmaceuticals Inc
 
ISI Business Profile
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California. Address: 2855 Gazelle Court, Carlsbad, CA, United States, 92010
 
© 2005-2023 BazaarTrend.com All rights reserved.

Data and information is provided for informational purposes only, and is not intended for trading purposes.
Neither BazaarTrend.com website nor any of its promoters shall be liable for any errors
or delays in the content, or for any actions taken in reliance thereon. Your use of this website constitutes
acceptance of our Terms Of Service